Other Events ·
ProQR to present clinical data for AX-0810 and preclinical progress on AX-0811 at upcoming conferences
PRQRProQR Therapeutics N.V.
ProQR Therapeutics announced it will present clinical and preclinical updates for its RNA editing programs at three major events. The company will showcase ADAR-mediated RNA editing advances at TIDES Europe in November, followed by Phase 1 data for the NTCP-targeting oligonucleotide AX-0810 at AASLD The Liver Meeting 2026. Additionally, Cohort 3 results and new preclinical proof-of-concept data for the next-generation candidate AX-0811 will be presented in December. Initial clinical data for AX-0811 is expected in early January 2027. ProQR Therapeutics operates as a clinical-stage biotechnology company developing transformative RNA therapies using its proprietary Axiomer platform.